Prevalence of COVID-19 Infection in a Cohort of Patients Infected by the HIV and Patients Taking PrEP

Official Title

Prevalence of COVID-19 Infection in a Cohort of Patient Infected by the HIV and Patients Taking PrEP Pre-exposure Prophylaxis

Brief Summary

The purpose of the study is to assess seroprevalence of COVID-19 infection in a cohort of HIV + patients and in a cohort of patients taking PrEP by emtricitabine / tenofovir.

Status

Unknown status

Conditions

COVID19

Virus-HIV

Interventions

Diagnostic Test: Serology test for COVID-19

ELISA test

Eligibility Criteria

Inclusion Criteria:

- Aged ≥ 18 years

- patients infected by the HIV on treatment

- patients taking PreP (Pre-exposure prophylaxis (PrEP))

- Being affiliated with or benefiting from a social security scheme

Exclusion Criteria:

- Subject to a measure for the protection of justice

Eligibility Gender

All

Eligibility Age

Minimum: 18 Years ~ Maximum: N/A

Countries

France

Locations

BENNANI
Marseille, France

Contacts

Myriam BENNANI
0413428351
m.bennani@hopital-europeen.fr

Investigators

Patrick PHILIBERT, Principal Investigator
Hôpital Europeen Marseille

NCT Number

NCT04575545

MeSH Terms

COVID-19

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

Hôpital Européen Marseille

Prevalence of COVID-19 Infection in a Cohort of Patients Infected by the HIV and Patients Taking PrEP

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA